Stifel Nicolaus Increases Artivion (NYSE:AORT) Price Target to $25.00

Artivion (NYSE:AORT) had its target price upped by analysts at Stifel Nicolaus from $22.00 to $25.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 7.16% from the company’s current price.

Separately, Needham & Company LLC boosted their price target on Artivion from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday.

Artivion Trading Down 1.9 %

NYSE:AORT opened at $23.33 on Tuesday. The company has a debt-to-equity ratio of 1.10, a current ratio of 4.85 and a quick ratio of 3.43. Artivion has a fifty-two week low of $12.16 and a fifty-two week high of $25.51. The stock’s 50-day moving average is $20.57 and its two-hundred day moving average is $18.18. The stock has a market cap of $961.20 million, a PE ratio of -31.11 and a beta of 1.66.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.02 by $0.04. The business had revenue of $97.43 million during the quarter, compared to analysts’ expectations of $92.30 million. Artivion had a positive return on equity of 3.02% and a negative net margin of 8.67%. During the same quarter in the previous year, the business posted $0.02 EPS. As a group, equities research analysts forecast that Artivion will post 0.26 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Marshall S. Stanton sold 2,183 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $20.39, for a total value of $44,511.37. Following the completion of the sale, the senior vice president now directly owns 83,296 shares in the company, valued at approximately $1,698,405.44. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CAO Amy Horton sold 1,695 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $18.86, for a total transaction of $31,967.70. Following the completion of the transaction, the chief accounting officer now directly owns 122,345 shares in the company, valued at $2,307,426.70. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Marshall S. Stanton sold 2,183 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $20.39, for a total value of $44,511.37. Following the transaction, the senior vice president now owns 83,296 shares of the company’s stock, valued at $1,698,405.44. The disclosure for this sale can be found here. In the last ninety days, insiders sold 149,952 shares of company stock worth $2,891,627. 8.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP lifted its holdings in shares of Artivion by 5.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,686,502 shares of the company’s stock worth $30,156,000 after buying an additional 80,214 shares during the last quarter. Wasatch Advisors LP increased its position in shares of Artivion by 108.8% during the first quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock valued at $22,928,000 after purchasing an additional 564,549 shares during the period. First Eagle Investment Management LLC increased its position in shares of Artivion by 37.3% during the third quarter. First Eagle Investment Management LLC now owns 526,528 shares of the company’s stock valued at $7,982,000 after purchasing an additional 143,146 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Artivion by 2.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 326,085 shares of the company’s stock valued at $5,830,000 after purchasing an additional 8,090 shares during the period. Finally, Principal Financial Group Inc. increased its position in shares of Artivion by 5.0% during the first quarter. Principal Financial Group Inc. now owns 220,445 shares of the company’s stock valued at $4,665,000 after purchasing an additional 10,479 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.